BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc.
WKN: 924801 / Symbol: BMRN / Name: BioMarin Pharmaceutical / Aktie / Pharmazeutika / Large Cap /
50,90 €
-0,86 %
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $97.00 to $96.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $113.00 to $114.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Guggenheim from $101.00 to $106.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Raymond James Financial, Inc.. They set an "outperform" rating and a $85.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at JPMorgan Chase & Co. from $116.00 to $119.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Barclays PLC from $86.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Morgan Stanley from $104.00 to $98.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Stifel Nicolaus from $91.00 to $73.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Wells Fargo & Company from $90.00 to $70.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $80.00 price target on by analysts at Truist Financial Corporation. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Neueste Beiträge
SVB_Leerink_LLC in Ultragenyx Pharmaceutical Inc. diskutieren